AdAlta (ASX:1AD) Valuation Rank

View and export this data going back to 2016. Start your Free Trial

What is AdAlta Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

Three factors:
- Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
- Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
- Industry relative valuation
Companies without enough data is not ranked
Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

AdAlta Valuation Rank Related Terms

Thank you for viewing the detailed overview of AdAlta's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

AdAlta (ASX:1AD) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AdAlta Ltd (ASX:1AD) » Definitions » Valuation Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

2 Park Drive, Unit 15, Bundoora, VIC, AUS, 3083

Website

https://www.adalta.com.au

AdAlta Ltd is engaged in drug discovery and development company developing protein therapeutics, known as i-bodies, for treating a wide range of human diseases. The i-body candidate, AD-214, is being developed for the treatment of idiopathic pulmonary fibrosis and other fibrotic diseases, for which current therapies are sub-optimal. Its pipeline includes Fibrosis, and CAR-T cancer therapeutics.